The Company’s product development pipeline includes the allergy portfolio, being developed by Astellas Pharma.

In addition, a number of companies and academic laboratories have been developing applications for LAMP-Vax in oncology including a study sponsored by our partner and licensee, the Geron Corporation (now Asterias), in leukemia patients (AML).

The pipeline below illustrates the current status of Immunomic Therapeutics’ clinical development program. Oncology and infectious disease products are in development by academics and corporate partners.